Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study

• Published in: The Lancet infectious diseases Vol. 23; no. 11; pp. 1235 - 1243
• Main Authors: Kirsebom, Freja Cordelia Møller, Andrews, Nick, Stowe, Julia, Ramsay, Mary, Lopez Bernal, Jamie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.11.2023; Elsevier Limited
• Subjects: Adults; Antibodies; Case studies; COVID-19; COVID-19 vaccines; Effectiveness; Health services; Hospitalization; Hospitals; Immunization; Infectious diseases; mRNA; Patients; Respiratory tract infection; Severe acute respiratory syndrome coronavirus 2; Vaccine efficacy; Vaccines; United Kingdom > UK; England; United States > US

Bivalent BA.1 booster vaccines were offered to adults aged 50 years or older and clinically vulnerable people as part of the 2022 autumn COVID-19 booster vaccination programme in England. Previously, all adults in England had been offered a primary course consisting of two doses of either ChAdOx1-S...